Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Commentary|Articles|May 20, 2026
Stay Ahead of ASCO 2026: See What Gynecologic Oncologists Are Prioritizing
Author(s)Caroline Seymour
Fact checked by: Courtney Flaherty
Discover which gynecologic cancer abstracts experts believe may affect evolving treatment paradigms and patient care discussions at ASCO 2026.
Advertisement
Advertisement
As the oncology community prepares to convene in Chicago for the 2026 ASCO Annual Meeting, OncLive® asked gynecologic oncology experts to identify the presentations they anticipate will drive discussion, inform practice, and spotlight emerging advances in the treatment of patients with gynecologic cancers.
Related to this article
The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.
The regulatory path to approval for RP1 plus nivolumab in anti–PD-1–pretreated melanoma ran through 3 BLAs, 2 CRLs, and a divided advisory committee vote.
The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement